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Background. Recent studies have favored the use of cefazolin over nafcillin for the treatment of methicillin-susceptible 
Staphylococcus aureus (MSSA) bacteremia. The clinical influence of the cefazolin inoculum effect (CzIE) in the effectiveness of ceph-
alosporins for severe MSSA infections has not been evaluated.
Methods. We prospectively included patients from 3 Argentinian hospitals with S.  aureus bacteremia. Cefazolin minimum 
inhibitory concentrations (MICs) were determined at standard (105 colony-forming units [CFU]/mL) and high (107 CFU/mL) inoc-
ulum. The CzIE was defined as an increase of MIC to ≥16 µg/mL when tested at high inoculum. Whole-genome sequencing was 
performed in all isolates.
Results. A total of 77 patients, contributing 89 MSSA isolates, were included in the study; 42 patients (54.5%) had isolates with 
the CzIE. In univariate analysis, patients with MSSA exhibiting the CzIE had increased 30-day mortality (P = .034) and were more 
likely to have catheter-associated or unknown source of bacteremia (P = .033) compared with patients infected with MSSA isolates 
without the CzIE. No statistically significant difference between the groups was observed in age, clinical illness severity, place of 
acquisition (community vs hospital), or presence of endocarditis. The CzIE remained associated with increased 30-day mortality in 
multivariate analysis (risk ratio, 2.65; 95% confidence interval, 1.10–6.42; P = .03). MSSA genomes displayed a high degree of heter-
ogeneity, and the CzIE was not associated with a specific lineage.
Conclusions. In patients with MSSA bacteremia where cephalosporins are used as firstline therapy, the CzIE was associated with 
increased 30-day mortality. Clinicians should be cautious when using cefazolin as firstline therapy for these infections.
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Staphylococcus aureus is one of the most important human 
pathogens and causes a variety of infections with diverse clin-
ical presentations [1]. Morbidity and mortality associated with 
severe infections caused by S.  aureus are substantial [2, 3], 
and in several parts of the world (including some areas of 
the United States), the frequency of methicillin-suscepti-
ble S. aureus (MSSA) infections is surpassing that of methi-
cillin-resistant S.  aureus (MRSA) [4, 5]. Despite causing an 
important burden of disease, there have not been major recent 
advances in the treatment of MSSA infections. Indeed, the 
mortality associated with MSSA infective endocarditis (IE) 
has not substantially changed in the last 20 years according to 
the International Collaboration on Endocarditis database (ca. 
23%) [6]. In the mid-1960s, cephalothin and cephaloridine 
were introduced as the main drugs against MSSA. However, 
early on, it was noted that cephaloridine activity was impaired 
against penicillin-resistant S.  aureus strains when tested at 
high inoculum [7, 8]. A case of failure of cephaloridine in the 
treatment of MSSA endocarditis supported the initial con-
cerns of cephalosporin treatment in deep-seated infections 
caused by MSSA [9].
The cephalosporin inoculum effect is defined as a prominent 
rise in the antibiotic minimum inhibitory concentration (MIC; 
to ≥16 µg/mL) when the susceptibility test is performed with 
an inoculum higher than the standard recommended bacter-
ial inoculum (~107 colony-forming units [CFU]/mL vs ~105 
CFU/mL) [10]. When cefazolin came into commercial use in 
the United States in 1971, it was noted that several penicilli-
nase-producing MSSA strains were able to readily hydrolyze 
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this drug [11–14]. Subsequently, cases of S. aureus endocarditis 
failing cefazolin therapy were described [15–17]. Of note, in 1 
of these cases, the MSSA strain exhibited high MICs of cefazo-
lin when a large inoculum was used (cefazolin inoculum effect 
[CzIE]) [18]. Initial studies [19, 20] carried out in the 1970s and 
1980s focused on the characterization of the S. aureus β-lacta-
mases. Initially, typing of such enzymes (BlaZ) was based on 
immunological methods with 4 different serotypes (A, B, C, and 
D) described [19]. Subsequently, typing was performed based 
on limited sequences of BlaZ and some support by kinetic stud-
ies that involved hydrolysis of different β-lactams [21, 22]. From 
those studies, type A BlaZ seemed to be more efficient in hydro-
lyzing cefazolin, and the preferred substrate for type C BlaZ was 
cephalothin.
Despite this limitation of the cephalosporins, the availabil-
ity of isoxazolyl penicillins (at least in the United States) with 
excellent stability against BlaZ has made such concerns less 
clinically relevant. Cefazolin has been used as second-line ther-
apy, often after patients have received a course of isoxazolyl pen-
icillins or, rarely, as firstline treatment if severe penicillin allergy 
is suspected. In these scenarios, the clinical importance of the 
inoculum effect has been difficult to assess. However, in recent 
years, several studies have suggested that cefazolin has clinical 
efficacy similar to nafcillin with a lower rate of adverse events, 
greater ease of administration, lower costs, and, most impor-
tantly, decreased mortality [23–29]. These data have prompted 
some clinicians to use cefazolin now as firstline therapy for 
severe MSSA infections.
Unlike the United States, isoxazolyl penicillins are not avail-
able in Argentina, and the vast majority of MSSA infections 
are treated with cephalosporins, making this country an ideal 
setting to evaluate the effect of the CzIE in patients with deep-
seated MSSA infections. Our previous published data indicate 
that there is a strong association between the CzIE and relapses 
in deep-seated MSSA infections [17] and failure to eradicate 
MSSA from the bloodstream in patients undergoing hemodi-
alysis [30]. Moreover, using a rat endocarditis model, we have 
clearly shown that the CzIE has important consequences for 
the efficacy of cefazolin in vivo [31], a finding that has been 
replicated by others [32]. Here, using a prospective cohort of 
patients with Staphylococcus aureus bacteremia in Argentina, 
we assessed the clinical impact of the CzIE with an emphasis 
on mortality.
METHODS
Study Design
We included adult patients admitted to 3 hospitals located in 
Buenos Aires, Argentina, from January 2011 to July 2014 with 
bacteremia caused by S. aureus (at least 1 positive blood cul-
ture was required). These patients were part of a previously 
published observational prospective cohort study of S. aureus 
bacteremia in Latin America [33]. Each patient contributed 1 
episode of bacteremia, defined as the 14-day period after the 
first positive blood culture was obtained, and all isolates col-
lected during this period were included in the genomic ana-
lysis. Excluded patients included those with polymicrobial 
bacteremia, a previous episode of bacteremia (relapse outside 
the 14-day period), those who were transferred from other 
institutions with bacteremia at the time of transfer, and those 
who were discharged from the hospital or died within the 
first 48 hours of the initial diagnosis. The institutional review 
boards of Universidad Peruana Cayetano Heredia in Lima, 
Peru (Data Collection Center), and of participating hospitals in 
Argentina approved the study. Demographic information was 
collected for all patients and included age, sex, source of bac-
teremia, place of acquisition (hospital, community, or health 
care associated according to the Centers for Disease Control 
and Prevention definition [34]), Charlson comorbidity score, 
Pitt bacteremia score, presence or absence of complicated 
bacteremia (as previously defined [33]) or endocarditis (as 
per the treating physician), and antibiotics used for definitive 
therapy (Table  1). The dosing of antimicrobial agents was at 
the discretion of the treating physicians, and this information 
was not collected specifically for logistical reasons. The usual 
dosing of cefazolin and cephalotin (2 cephalosporins avail-
able in Argentina intravenously) for severe MSSA infections in 
Argentina is 2 grams every 8 hours and 2 grams every 6 hours, 
respectively, adjusted for renal function. The major outcomes 
of interest were all-cause mortality at 7 and 30 days after the 
initial blood culture.
Microbiological, Molecular, and Genomic Characterization of S. aureus 
Isolates
All S.  aureus isolates were identified by standard microbio-
logical techniques at the local hospital and subsequently sent 
to a reference laboratory (Universidad El Bosque, Bogota, 
Colombia) for additional characterization and confirmation of 
identification using a previously described multiplex polymer-
ase chain reaction (PCR) assay [35]. Minimal inhibitory con-
centrations (MICs) of cefazolin were determined with standard 
(~5 × 105 CFU/mL) and high (~5 × 107 CFU/mL) inocula via 
the broth microdilution method, as previously described, and 
the maximum antibiotic concentration tested for cefazolin was 
64  µg/mL [36]. The presence of the CzIE was defined as an 
increase in the MIC to ≥16  µg/mL when performed at high 
inoculum. If patients had more than 1 MSSA isolate recov-
ered from the same set of blood cultures, the presence of the 
CzIE in any isolate was sufficient to categorize the patient as 
having an infection with an organism exhibiting the CzIE. All 
MIC determinations were performed in triplicate and read 
by 3 independent observers. The following were included as 
controls: S. aureus TX0117, a CzIE-positive isolate with type 
A  β-lactamase, S.  aureus ATCC 29213, a strain possessing a 
type A  β-lactamase without the CzIE; and S.  aureus ATCC 
25923, a BlaZ-negative strain.
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Table 1. Comparison of Clinical Characteristics of Patients With MSSA Bacteremia Exhibiting and Not Exhibiting the Cefazolin High Inoculum Effecta
Characteristic No CzIE CzIE P Value
No. (%) 35 (45.5) 42 (54.5)
Age, mean (SD), y 66.9 (11.7) 66.9 (19.6) .992
Male gender 23 (65.7) 24 (57.1) .488
Source of bacteremia .033
 Primary 8 (22.9) 20 (47.6)
 Secondary 27 (77.1) 22 (52.4)
Central venous catheter–related primary bacteremia 7 (20.0) 15 (35.7) .129
Source of secondary bacteremia
 Respiratory 7 (20.0) 9 (20.0) .878
 Skin 3 (8.6) 2 (4.8) .499
 Surgical 1 (2.9) 3 (7.1) .398
 Endovascular 8 (22.9) 8 (19.0) .682
 Bone/joint 5 (14.3) 4 (9.6) .517
 Urinary 1 (2.9) 1 (2.4) .896
 Abdominal 4 (11.4) 1 (2.4) .227
 Central nervous system 0 (0.0) 0 (0.0) —
Place of acquisition .795
 Community 8 (22.9) 7 (16.7)
 Hospital 14 (40.0) 17 (40.5)
 Health care related 13 (37.1) 18 (42.9)
Comorbidities in the 3-mo period before diagnosis of bacteremia
 Cancer 12 (34.3) 12 (28.6) .628
 Transplant 0 (0.0) 0 (0.0) —
 AIDS 1 (2.9) 0 (0.0) .455
 Myocardial infarction 1 (2.9) 2 (4.8) 1.000
 Heart failure 7 (20.0) 6 (14.3) .553
 Peripheral vascular disease 6 (17.1) 9 (21.4) .775
 Diabetes 6 (17.1) 11 (26.2) .414
 Lung disease 7 (20.0) 8 (19.1) 1.000
 Burn 1 (2.9) 0 (0.0) .455
 Liver disease 4 (11.4) 3 (7.1) .695
 Kidney disease 9 (25.7) 18 (42.9) .152
 Neurological disorder 2 (5.7) 2 (4.8) 1.000
 Gastric/duodenal ulcer 0 (0.0) 0 (0.0) —
 Connective tissue disease 0 (0.0) 4 (9.5) .121
 Previous surgery 10 (28.6) 12 (28.6) 1.000
 Immunosuppressive therapy 7 (20.0) 10 (23.8) .786
 Other comorbidities 10 (28.6) 10 (23.8) .795
Previous S. aureus infection 0 (0.0) 3 (7.1) .246
Hospitalization within prior 3 mo 19 (54.3) 13 (31.0) .062
Use of antimicrobials 30 d before admission 12 (34.3) 7 (16.7) .111
Ward of admission 1.000
 Medical 28 (80.0) 34 (81.0)
 Surgical 4 (11.4) 5 (11.9)
 Obstetrics–gynecology 0 (0.0) 0 (0.0)
 Emergency room 3 (8.6) 3 (7.1)
 Other 0 (0.0) 0 (0.0)
Clinical condition 48 h before blood sampling
 Mechanical ventilation 1 (2.9) 4 (9.5) .369
 Central venous catheter in place 10 (28.6) 16 (38.1) .470
 Parenteral nutrition 1 (2.9) 3 (7.1) .621
 Surgical procedure 0 (0.0) 1 (2.4) 1.000
 Dialysis 4 (11.4) 11 (26.2) .150
 Severe sepsis 6 (17.1) 12 (28.6) .287
Charlson comorbidity scale, median (IQR) 2 (1–3) 2 (1–3) .818
 Score >2 14 (40) 15 (35.7) .814
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Genomic DNA libraries were prepared using the NexteraXT 
kit (Illumina) and whole-genome sequencing performed with 
250-bp paired-end reads on an Illumina MiSeq sequencer. 
Assemblies were done using Spades v3.11 [37]. We performed 
in silico multilocus sequence typing (MLST) with the mlst-
tool (https://github.com/tseemann/mlst) using the scheme for 
Staphylococcus aureus from PUBMLST [38]. Identification of 
the BlaZ protein sequence was done with BlastX using the ref-
erence sequence WP_000733289.1 from the NCBI. Typing of 
BlaZ was carried out by identification of the amino acid residues 
in positions 128 and 216 [22]. Phylogenetic reconstruction of all 
sequenced genomes using the core genome was performed with 
RAxML, based on RAST annotations [39, 40]. The best tree of 
20 runs using a general time-reversible evolution model and a 
gamma model of rate heterogeneity with 100 bootstrap resam-
pling was rooted at the midpoint and plotted with iTOL [41].
Statistical Analyses
Data analyses were carried out using Stata v 8.2 (College 
Station, TX). Univariate associations comparing patients with 
isolates exhibiting the CzIE vs those who did not exhibit this 
phenotype were explored using the Student t, Kruskal-Wallis, 
and Fisher exact test. Risk ratios were calculated to compare 
cumulative mortality between patients infected with MSSA 
isolates exhibiting the CzIE vs no CzIE. Stratified analysis was 
carried out using Mantel-Haenszel. Adjusted risk ratios were 
calculated to detect confounders, and the Breslow and Day tests 
were used to detect potential effect modifiers of the association 
between the presence of the CzIE and 30-day all-cause mortal-
ity. As no variable had a significant value in the test of homoge-
neity of risk ratio, no further evaluation of effect modification 
was performed. All variables that changed the crude risk ratio 
by more than 10% were considered potential confounders and 
were included in a multivariate model using a generalized linear 
fixed model by link “log.” Variables with the highest P values 
were removed in a stepwise fashion, until no variables with P 
values higher than .05 remained in the model. Age in years was 
categorized as ≤60, 61–80, and ≥81 for the stratified analysis. In 
the multivariate analysis, age was evaluated as a linear and as a 
quadratic term.
RESULTS
A total of 77 patients with MSSA bacteremia contributing 89 
MSSA isolates were included in the analysis. Overall, 67 patients 
contributed an initial bloodstream isolate, 8 patients had 2 
recovered isolates, and 2 patients had 3 isolates. The cefazolin 
MIC90 for all isolates when tested at standard inoculum was 
Characteristic No CzIE CzIE P Value
McCabe Jackson scale .689
 Rapidly fatal 4 (11.4) 5 (11.9)
 Ultimately fatal 14 (40.0) 21 (50.0)
 Nonfatal 17 (48.6) 16 (38.1)
APACHE II score, median (IQR) 10 (0–12) 4 (0–13) .629
 Score >0 8 (22.9) 9 (21.4) 1.000
 Pittsburg score, median (IQR) 1 (0–1) 1 (0–2) .440
 Score >1 8 (22.9) 13 (31.0) .454
Intensive care unit admission during current hospitalization 13 (37.1) 18 (42.9) .647
Trans-thoracic echocardiography performed 30 (85.7) 31 (73.8) .263
Duration of fever, median (IQR), d 3 (2–4) 3 (2–4) .398
Total white blood cells × 103, median (IQR)e 11.0 (6.9–14.6) 9.6 (7.4–15.1) .701
Creatinine, median (IQR), mg/dl 0.9 (0.6–1.4) 1.4 (0.9–3.5) .005
Glucose, mean (SD), mg/dl 116.6 (66.6) 131.4 (81.1) .391
Complicated bacteremia 7 (20.0) 8 (19.1) 1.000
Focus of complicated bacteremia
 Infective endocarditis 2 (5.7) 6 (14.3) .280
 Others 5 (14.3) 2 (5.7) .139
7-d all-cause mortality 2 (5.7) 5 (11.9) .445
30-d all-cause mortality 5 (15.2) 15 (39.5) .034
Antibiotics used for definitive treatment .261
 Vancomycin monotherapy 2 4
 Cephalosporins 22 31
 Combination therapy 8 3
 Other 3 4
Abbreviations: CzIE, cefazolin inoculum effect; IQR, interquartile range; MSSA, methicillin-susceptible Staphylococcus aureus.
aValues are No. (%) unless noted otherwise.
Table 1. Continued
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1 µg/mL. A total of 42 (54.5%) patients harbored isolates that 
exhibited the CzIE. Among the CzIE patients, 7 had more than 
1 isolate recovered from blood cultures, but genomic analyses 
indicated that each set of isolates belonged to the same sequence 
type (ST) and that they were closely related in the phylogenetic 
reconstruction (Figure 1). The average increase in the cefazolin 
MIC for isolates that exhibited the CzIE when tested at high 
inoculum was 85.3-fold (isolates with cefazolin MIC >64 µg/mL 
were given a value of 128 µg/mL).
Table 1 shows that patients infected with isolates that exhib-
ited the CzIE had similar characteristics to those who did not. 
Notable exceptions were that a higher number of patients in the 
CzIE group developed a primary bacteremia associated with a 
catheter or from an unknown source (P = .03) and that the CzIE 
group had a significantly higher baseline creatinine level (0.9 
vs 1.4, P = .005). Importantly, baseline comorbidities (Charlson 
comorbidity index [42]) severity of bacteremia (assessed by 
APACHE II [43], McCabe Jackson score [44], and Pittsburgh 
bacteremia score [45]), diagnosis of infective endocarditis (IE), 
admission to the intensive care unit, and prescribed antibiotics 
for definite therapy were similar between the groups. Although 
no difference in 7-day all-cause mortality was seen between 
High Inoculum Eect
BlaZ type
Present
A
B
C
D
Nontypeable
No detected
Tree scale: 0.001
Absent
Figure 1. Phylogenetic tree of the core genome of 89 Argentinian methicillin-susceptible Staphylococcus aureus isolates and 3 control sequences. The outermost circle 
denotes the BlaZ type for each β-lactamase; isolates without a β-lactamase are left blank. The outer-middle circle shows the presence (black) or absence (white) of the 
cefazolin inoculum effect (CzIE) in each isolate. The inner-middle circle lists the sequence type, and the innermost circle lists the name for each isolate; single isolates are col-
ored white, and paired isolates from the same patient are colored gray. The light blue circles at each branch point show the bootstrap support values, varying from 70 to 100.
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the groups, patients infected with isolates exhibiting the CzIE 
had a statistically significantly higher 30-day mortality com-
pared with those patients infected with MSSA lacking the CzIE 
(39.5% vs 15.2%, P = .034).
To explore clinical factors associated with 30-day all-cause 
mortality, we performed bivariate and multivariate analyses 
using a generalized linear fixed model (Table  2). In the mul-
tivariate model, the presence of the CzIE, when adjusted 
for potential confounders, continued to be associated with 
increased 30-day all-cause mortality (risk ratio [RR], 2.65; 95% 
confidence interval [CI], 1.10–6.42; P = .03). The only other sig-
nificant factor in the multivariate analysis was an association 
between increased 30-day all-cause mortality and a secondary 
source of bacteremia (RR, 2.15; 95% CI, 1.01–4.57; P = .047). 
After performing a stratified analysis for age, a trend toward 
increased 30-day mortality was seen with age >81 years, though 
this did not reach significance (RR, 4.77; 95% CI, 0.97–23.44; 
P = .055). As a significant difference in baseline creatinine was 
seen on univariate analysis and acute kidney injury has been 
independently associated with mortality [46], we included 
serum creatinine >1.0  mg/dL as a variable in the analysis. In 
both bivariate and multivariate models, a serum creatinine level 
of >1.0 mg/dL was not associated with increased risk of 30-day 
mortality.
Figure  1 shows the core genome phylogenetic reconstruc-
tion of the 89 MSSA isolates recovered from the 77 patients and 
the 3 control strains (n  =  92) using whole-genome sequenc-
ing. Approximately one-third of the total recovered isolates 
belonged to CC5, CC30, and CC8, lineages whose members 
include the successful MRSA epidemic clones described in 
Argentina [47]. However, the overall population structure of 
MSSA displayed more heterogeneity as compared with a recent 
analysis of MRSA strains from this same region [47]. The pres-
ence of the CzIE was not restricted to a limited set of sequence 
types, suggesting that this phenomenon is not due to the clonal 
spread of a particular hospital-adapted clone. As reported pre-
viously, the CzIE was associated most strongly with type A and 
type C β-lactamase. Interestingly, almost all isolates (8/9, 88.9%) 
from ST188 possessed a type C β-lactamase and displayed the 
CzIE; in addition, a large proportion of ST30 (15/20, 75%) and 
ST8 (11/15, 73.3%) isolates (which predominately carried type 
A enzymes) were also CzIE positive. None of the 8 ST5 isolates 
(harboring predominately type B β-lactamase) sequenced were 
found to be resistant to cefazolin at high inoculum. Of note, 
we also identified 3 isolates with type B β-lactamase and 1 with 
type D β-lactamase that display the inoculum effect, an associ-
ation that has not been described in previous studies.
DISCUSSION
In this prospective cohort study of patients with MSSA bacter-
emia, the presence of the CzIE in the infecting isolate was asso-
ciated with a statistically significant increase in 30-day all-cause 
mortality. Unlike previous reports, our study directly addresses 
the question of whether the presence of the CzIE negatively 
affects patient survival. Prior studies of cefazolin vs nafcillin for 
MSSA bacteremia have largely focused on retrospective clinical 
data, with limited or no microbiologic information, including 
evaluation of the presence of the CzIE [23–25, 29]. One retro-
spective study analyzed 113 patients with MSSA bacteremia 
whose isolates were available for testing. In this study, 57.5% 
of isolates were positive for the CzIE (defined by the authors of 
the study as a 4-fold or greater increase in cefazolin MIC at high 
inoculum), and although there was a trend toward increased 
treatment failures in CzIE-positive isolates (48% vs 25%), this 
did not reach statistical significance [27]. The failure to reach 
statistical significance may be due to the fact that the CzIE as 
defined in this study did not require the isolate to be above 
the susceptibility cutoff. A  recent prospective study of nafcil-
lin vs cefazolin by the same group included a small subset of 
patients treated with cefazolin for which the presence of CzIE 
in the isolate was assessed [28]. Overall, 22.4% of isolates were 
positive for the CzIE, and those treated with cefazolin, but not 
nafcillin, were statistically more likely to have clinical failure or 
death within 1 month of positive culture when infected with a 
Table 2. Bivariate and Multivariate Analysis of Factors Associated With 30-Day All-Cause Mortality
Variable Crude RR 95% CI P Value Adjusted RR 95% CI P Value
Presence of the CzIE 2.61 0.91–7.45 .074 2.65 1.10–6.42 .030
Age, y
 ≤60 Ref Ref
 61–80 2.11 0.32–13.82 .436 1.63 0.32–8.29 .554
 ≥81 5.94 0.98–36.14 .053 4.77 0.95–23.44 .055
High Charlson score 1.23 0.58–2.60 .594 1.99 0.95–4.19 .069
Previous hospitalization 1.12 0.53–2.37 .771 0.90 0.46–1.74 .751
Pittsburgh bacteremia score 1.17 1.00–1.35 .045 1.09 0.93–1.27 .292
Previous S. aureus infection 1.19 0.24–5.89 .828 1.25 0.44–3.57 .676
Secondary source of bacteremia 1.43 0.60–3.45 .423 2.15 1.01–4.57 .047
Serum creatinine >1.0 mg/dl 2.20 0.79–6.12 .133 1.59 0.76–3.31 .219
Abbreviations: CI, confidence interval; CzIE, cefazolin inoculum effect; RR, risk ratio. 
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CzIE-positive isolate. Our results provide further evidence that 
use of cephalosporins for MSSA isolates that display the CzIE 
may be associated with worse clinical outcomes. Additionally, 
our study reiterates the importance of source control in man-
aging staphylococcal infections, as a secondary source of bac-
teremia was the only other significant variable associated with 
treatment failure. In the context of the CzIE, source control 
would provide a reduction of the bacterial inoculum, as well 
as potentially improving efficacy of antibiotics to the site of 
infection.
Of note, the number of isolates that tested positive for the 
CzIE was 54.5%, which is higher than the rates of 19% to 36% 
described in previous surveys [30, 36]. This increased prevalence 
may have allowed us to detect a difference between the 2 groups 
that would have gone unrecognized with a smaller number of 
isolates. Interestingly, we did not note a significant difference in 
the distribution of CzIE-positive MSSA isolates between com-
munity and hospital settings as compared with CzIE-negative 
isolates. This may reflect the significant heterogeneity observed 
in the population of MSSA isolates and the widespread presence 
of the CzIE. It is unclear if the higher prevalence of the CzIE 
in Argentina is associated with the use of cephalosporins for 
MSSA and represents an adaptation to the resultant selective 
pressure of these antibiotics. This could become an important 
question for active surveillance if cefazolin becomes front-line 
therapy in areas currently using isoxazolyl penicillins.
An important contribution of our study was the use of 
genomics to study the population structure of MSSA exhibiting 
the CzIE. Consistent with previous studies [48], there is a much 
wider heterogeneity of isolates represented as compared with 
MRSA infections, although sequence types ST8 and ST30 were 
predominant. Of particular interest, ST188–BlaZ type C was 
associated with the CzIE in almost all isolates we analyzed (8/9), 
though this could have been a consequence of nonrandom sam-
pling. Interestingly, the presence of type A β-lactamase seems to 
be more associated with ST30 and ST8 whereas type C was more 
associated with ST188. Previous studies have linked the CzIE 
to dysfunction of the accessory gene regulator (agr) locus, an 
important density-dependent quorum sensing system that regu-
lates genes that encode autolysins and secreted virulence factors, 
among others [49]. In vitro studies have shown that methi-
cillin-resistant strains deficient in agr function more readily 
form biofilm on polystyrene plates and display increased resist-
ance to host-derived cationic antimicrobial peptides [50, 51]. 
Clinically, agr dysfunction has been associated with prolonged 
bacteremia and mortality in S. aureus infections [52, 53]. Thus, 
further comparison of the genomic sequence data and phe-
notypic characterization of these isolates with other sequence 
types, such as ST5, which was not associated with the CzIE, 
may provide insight into the factors that drive this complex 
phenotype.
There are several limitations of our study. First, the patients 
were enrolled from a limited geographic area, and the collected 
isolates may not be representative of MSSA circulating in other 
parts of the world. In locations where a lower prevalence of the 
CzIE is present, the clinical impact might be less evident. Thus, 
the local prevalence of the CzIE must be taken into account 
when generalizing these results. Although the use of cephalo-
sporins in Argentina provides a unique opportunity to evaluate 
the clinical impact of the CzIE, it is unknown whether the use of 
other agents active against MSSA before initiation of cefazolin 
therapy would have a protective effect. Second, patient selection 
and treatment regimens were nonrandomized, thus introducing 
potential confounders to the data. One potential source of bias 
was the significant difference in renal function between the 2 
groups. Though the mean serum creatinine was noted to be dif-
ferent between the 2 groups, other measures of clinical comor-
bidities or illness severity were not different, and inclusion of 
creatinine did not result in a significant impact on mortality 
in either the bivariate or multivariate models. Although we 
attempted to control for this and other confounders by statis-
tical methods, further prospective randomized data are needed 
to confirm these initial findings. Third, we used the end points 
of 7-day and 30-day all-cause mortality to assess outcomes for 
the patients enrolled in this study. In the prior Latin American 
cohort [33], investigator-determined attributable mortality 
differed significantly from the per-protocol definitions, so this 
information was not used for the calculations in the current 
study to avoid subjective bias. Mortality data on 6 patients (4 
with and 2 without the CzIE) were not available. Due to the 
small number of outcomes, a conservative sensitivity analysis 
(assuming survival in those patients with CzIE and death in 
those without the effect) resulted in an unstable model. Thus, 
further prospective studies with a larger number of patients are 
needed to confirm these findings. Other potentially important 
outcomes, such as duration of bacteremia and microbiologic 
clearance, were not assessed in the current study.
In conclusion, the CzIE was associated with an increased 
risk of 30-day all-cause mortality in Argentinian patients with 
MSSA bacteremia. The unique clinical setting of Argentina, 
where cephalosporins are the firstline therapy for MSSA infec-
tions and isoxazolyl penicillins are not available, provides an 
ideal scenario in which to study the impact of the CzIE on clin-
ical outcomes. Although cefazolin may be acceptable as initial 
therapy in uncomplicated MSSA bacteremia with adequate 
source control, we urge caution in the selection of cefazolin for 
serious MSSA infections when a large burden of organisms or 
an unaddressed secondary focus of infection may be present. 
Rapid diagnostic tools to easily identify isolates with the CzIE 
in the clinical lab and further studies on which patients are at 
risk of failing cefazolin therapy in the presence of the CzIE are 
urgently needed.
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